Bharat Biotech Completes Indigenous Intranasal COVID-19 Vaccine Trial

New Delhi: Bharat Biotech on Monday announced that it has completed clinical development for phase III trials and booster doses for BBV154 intranasal covid vaccine.

“Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (two-dose) schedule; and a heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid vaccines in India,” the company said in a statement.

BBV154 (intra nasal vaccine) is a novel intranasal vaccine for Covid-19. It’s a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein.

This vaccine candidate was evaluated earlier in Phase I and II clinical trials with successful results.